History of OTI-2024 Drug Discovery and Development
OTI-2024 was previously developed by Inotek Pharmaceuticals (known as trabodenoson or INO-8775) in Massachusetts. It underwent four complete randomized control clinical trials (2009-2017), demonstrating its excellent clinical safety and MMP therapeutic potency. However, it failed in a prior Phase 3 IOP clinical trial, due to wrong dose and study design issues. Since June 2020, Dr. Qiu made new discoveries of trabodenoson- derived MMP therapeutic for treating the IOP failure and neural protection in glaucoma. She spent 18 months under stealth mode, patenting her inventions, before forming OTI LLC in November 2023.
Special OTI Taskforce Acknowledgements